Cullen/Frost Bankers, Inc. Arvinas, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.21 Billion
- Q4 2024
A detailed history of Cullen/Frost Bankers, Inc. transactions in Arvinas, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 281 shares of ARVN stock, worth $5,330. This represents 0.0% of its overall portfolio holdings.
Number of Shares
281
Previous 240
17.08%
Holding current value
$5,330
Previous $5,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ARVN
# of Institutions
228Shares Held
68.4MCall Options Held
226KPut Options Held
285K-
Vanguard Group Inc Valley Forge, PA7.06MShares$134 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$128 Million7.19% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$119 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.85MShares$73.1 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.78MShares$52.8 Million1.09% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $1.01B
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...